Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 2/20 | 0.36 |
| ▸ | NOS1 | P29475 | 2/20 | 0.36 |
| ▸ | NOS2 | P35228 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 2/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26498668 | 0.91 | PIK3CD (0.46) | PIK3CDNOS3NOS1NOS2SLC6A2 | |
| SCHEMBL21107431 | 0.84 | PIK3CD (0.49) | PIK3CDNOS3NOS1NOS2SLC6A2 | |
| SCHEMBL23696231 | 0.83 | PIK3CD (0.47) | PIK3CDNOS3NOS1NOS2SLC6A2 | |
| SCHEMBL22861707 | 0.81 | GNAO1 (0.47) | PIK3CDNOS3NOS1NOS2 | |
| SCHEMBL25923755 | 0.81 | PIK3CD (0.49) | PIK3CDNOS3NOS1NOS2KDM4E | |
| SCHEMBL22856093 | 0.80 | PIK3CD (0.52) | PIK3CDNOS3NOS1NOS2SLC6A2 | |
| SCHEMBL23696396 | 0.79 | GRIN2A (0.32) | — | |
| SCHEMBL23696170 | 0.79 | PIK3CD (0.50) | PIK3CDNOS3NOS1NOS2KDM4E | |
| SCHEMBL23696447 | 0.77 | GNAO1 (0.39) | NOS3NOS1NOS2SLC6A2SLC6A4 | |
| SCHEMBL21107432 | 0.75 | PIK3CD (0.53) | PIK3CDNOS3NOS1NOS2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | PIK3CD 321/4885NOS3 3425/4885NOS1 3662/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | PIK3CD 321/4885NOS3 3425/4885NOS1 3662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.